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Gerstmann-Sträussler-Scheinker 
disease subtypes efficiently 
transmit in bank voles as genuine 
prion diseases
Laura Pirisinu1, Michele A. Di Bari1, Claudia D’Agostino1, Stefano Marcon1, 
Geraldina Riccardi1, Anna Poleggi2, Mark L. Cohen3, Brian S. Appleby3, Pierluigi Gambetti3, 
Bernardino Ghetti4, Umberto Agrimi1 & Romolo Nonno1
Gerstmann-Sträussler-Scheinker disease (GSS) is an inherited neurodegenerative disorder associated 
with mutations in the prion protein gene and accumulation of misfolded PrP with protease-resistant 
fragments (PrPres) of 6–8 kDa. With the exception of a few GSS cases characterized by co-accumulation 
of PrPres of 21 kDa, efforts to transmit GSS to rodents have been unsuccessful. As a result, GSS 
subtypes exclusively associated with 6–8 kDa PrPres have often been considered as non-transmissible 
proteinopathies rather than true prion diseases. We show that GSS with P102L, A117V and F198S 
mutations transmit efficiently and produce distinct pathological phenotypes in bank voles  
(M. glareolus), irrespective of the presence of 21 kDa PrPres in the inoculum, demonstrating that GSS is a 
genuine prion disease characterized by both transmissibility and strain variation.
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative disorders asso-
ciated with the accumulation of PrPSc, a misfolded form of the cellular prion protein (PrPC). PrPSc is considered 
the main or exclusive component of infectious prions1. Creutzfeldt-Jakob disease (CJD) is the most common 
TSE in humans and may be inherited/genetic, acquired/iatrogenic, or sporadic. Inherited forms of human prion 
disease also include fatal familial insomnia (FFI) and Gerstmann–Sträussler–Scheinker disease (GSS), caused by 
pathogenic mutations in the prion protein gene (PRNP) believed to predispose mutant PrPC to convert sponta-
neously to PrPSc.
GSS is an autosomal dominant prion disease associated with point mutations in the prion protein gene 
(PRNP) and characterized pathologically by the deposition of prion protein amyloid in the brain accompanied by 
gliosis, neuronal loss, and variable amounts of spongiform degeneration2.
As a genetically encoded prion disease, GSS could provide the strongest evidence that the abnormal prion 
protein is the causative agent of prion disease. However, lack of successful transmission of several forms of GSS 
has cast significant doubt on this hypothesis3–6.
In most TSEs, proteinase K (PK) treatment of PrPSc results in PK-resistant aggregates (PrPres) composed of 
variably glycosylated C-terminal PrPres fragments, whose non-glycosylated PrPres show molecular weights of 
19-to-21 kDa7. In contrast, GSS subtypes are characterized by non-glycosylated PrPres composed of PrP internal 
fragments, truncated at N- and C- termini, whose molecular weight varies between 6 and 8 kDa, depending on 
the specific PRNP mutation8–10. The most frequent GSS mutation is a proline-to-leucine substitution at PRNP 
codon 102 (P102L). The GSS P102L phenotype was reported to be highly heterogeneous, and seminal studies 
suggested a correlation between pathological and molecular variability in these cases8. Indeed, two distinct phe-
notypes of GSS P102L have been described, with the accumulation of both 21 and 8 kDa PrPres in patients with 
spongiform degeneration, and 8 kDa PrPres only in patients lacking spongiform degeneration8,11. Importantly, 
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transmission studies suggested that the 21 kDa PrPres isoform was responsible for the biological properties of 
GSS, as only cases with 21 kDa PrPres were transmissible in wild-type mice6 and transgenic mice (Tg101LL) 
expressing mutated murine PrP equivalent to human P102L12, and always induced 21 kDa PrPres in the recip-
ient hosts. Brain extracts from GSS P102L patients with 8 kDa PrPres were not transmissible to wild-type mice, 
and induced PrP-amyloid deposition but did not replicate the TSE infectious agent in Tg101LL mice5. Similarly, 
GSS cases with PRNP mutations exclusively associated with atypical 6–8 kDa internal PrPres fragments have not 
been convincingly shown to induce prion propagation in the brains of new hosts after experimental challenge. 
Among these, GSS cases associated with A117V and F198S mutations show atypical PrPres fragments of 6–7 kDa 
and 8 kDa, respectively8–10,13. Several patients with the latter mutation variant were identified in a large Indiana 
kindred14 and are characterized by prominent PrP plaque deposition and tau-positive fibrillary tangles15–17. GSS 
A117V cases show a wide range of clinical and pathological presentations even within the same family18–21. A 
recent study reported partial transmission of GSS A117V cases to transgenic mice over-expressing the human 
117V PrP, characterized by low clinical attack rates, long incubation periods (> 600 days), and accumulation of 
inherently unstable PrPSc aggregates22.
Inefficient transmission of GSS cases with 6–8 kDa PrPres has led to the hypothesis that GSS is a 
non-transmissible proteinopathy rather than authentic prion disease5, implying that proteinopathies and prion 
diseases were associated with different isoforms of PrPSc. Indeed, recent studies suggest differences between 
cell-to-cell spread of misfolded proteins and the transfer of infectivity from one organism to another23, as well as 
between pathogenic and infectious properties of the prion protein itself 24. To address these issues, we attempted 
to transmit several biochemically characterized GSS cases10 to bank voles, a rodent model able to propagate 
most human and animal prion diseases25–33. We found that all GSS cases induced prion diseases characterized by 
spongiform degeneration, PrPSc deposition, and propagation of infectious agents in the brain of recipient voles, 
implying that GSS, similar to others TSEs, is associated with infectious prions.
Results
GSS with A117V mutation. Brain homogenates from two unrelated GSS cases with A117V mutation 
(Supplementary Table S1), both associated with small internal PrPres fragments of 6–7 kDa10, were inoculated in 
bank voles carrying isoleucine at PRNP codon 109 (Bv109I). Remarkably, both cases caused a rapidly progres-
sive and fatal neurological disease, with mean survival time of ~95 days post-inoculation (dpi) (Table 1). In all 
clinically-affected voles, neuropathological analysis showed spongiform degeneration, gliosis, and neuronal loss 
(Fig. 1). In the white matter (Fig. 1a,d), spongiform changes mainly involved the alveus, dorsal hippocampal com-
missure, anterior commissure, white matter bundles in striatum and pallidum and, to a lesser extent, the corpus 
callosum. Spongiform changes in grey matter appeared as microvacuoles in hippocampus and cerebral cortex 
(Fig. 1a,f), particularly in motor, piriform and entorhinal cortices. Variable involvement of cerebellar molecular 
layer was also observed. By immunohistochemistry, PrPSc deposition was mainly found in areas with spongiform 
changes, particularly in the alveus and dorsal hippocampal commissure (Fig. 1b). PrPSc deposits appeared as 
coarse, granular deposits in white matter tracts (Fig. 1e) and synaptic/punctuate deposits in grey matter areas 
(Fig. 1g) and were resistant to PK (Fig. 1c). Brain homogenates from diseased voles contained protease-resistant 
PrPSc easily detectable in standard western blot as small internal PrPres fragments of ~7 kDa truncated at both N- 
and C- termini (Supplementary Fig. S1). Notably, the PrPres electrophoretic pattern in voles inoculated with GSS 
A117V cases was very similar to that in the human inocula (Fig. 2a).
Intriguingly, sub-passage in voles showed survival times (Table 1) and neuropathological patterns 
(Supplementary Fig. S2) similar to those observed after primary transmission, suggesting that the human-to-vole 
species barrier did not affect the efficiency of transmission of GSS A117V.
Inoculum* Codon 129 PrPres type (kDa) Mean survival time ± SD (days) Attack rate, n/N°†
#1-A117V VV 6–7 95 ± 15 13/13
#2-A117V MV 6–7 95 ± 8 11/11
Bv- #1-A117V° 107 ± 6 12/12
Bv- #2-A117V° 111 ± 5 11/11
#3-F198S VV 8 143 ± 26 14/15
#4-F198S MV 8 153 1/13
#5-P102L MV 21 + 8 363 ± 38 6/8
#6-P102L-FC MM 21 + 8 265‡; 705 ± 58§ 8/12
#6-P102L-Cb MM 8 153 ± 9 5/12
#7-P102L-FC MV 8 208 ± 58 14/16
#7-P102L-Cb MV 8 171 ± 53 13/13
Table 1.  Transmission of GSS cases in bank voles. *Human inocula were prepared from the frontal cortex. 
For two GSS P102L cases inocula were prepared from both the frontal cortex (FC) and cerebellum (Cb). 
 †n, Number of mice that developed confirmed TSE disease; N° number of inoculated mice. °Second passages. 
‡Survival time of a single Bv109I that accumulated 7 kDa PrPres. §Survival time (mean ± SD) of Bv109I that 
accumulated 21 kDa PrPres.
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GSS with F198S mutation. Brain homogenates from two F198S patients from the same kindred 
(Supplementary Table S1) were inoculated into Bv109I. Case #3 caused fatal neurological disease in 14/15 ani-
mals after a mean survival period of 143 dpi (Table 1). In contrast, case #4 transmitted the disease in only one vole 
that showed terminal neurological disease after 153 dpi (Table 1). All other inoculated Bv109I were still alive and 
healthy after 800 dpi, or were sacrificed for intercurrent disease and found negative for PrPSc. The lower amount 
of PrPres detected in the inoculum from case #4 compared to case #3 might explain the different attack rates 
(Supplementary Fig. S3). In all affected voles, neuropathological, immunohistochemical and western blot analy-
ses revealed PrPres molecular signature (Fig. 2b), spongiform degeneration (Fig. 3a) and PrPSc deposition patterns 
(Fig. 3b,c) similar to those observed in Bv109I inoculated with GSS A117V. Direct comparison of PrPres types 
revealed a downward shift from ∼ 8 to ~7 kDa in vole-passaged PrPSc compared to the human inocula (Fig. 2b).
Figure 1. Histological and immunohistochemical analysis of Bv109I infected with A117V. Sections of the 
hippocampus (a–c), the anterior commissure (d,e) and the piriform cortex (f,g) were analyzed by haematoxylin 
& eosin staining (a,d,f), by immunohistochemistry for PrPSc (b,e,g) and by PET-blot for protease-resistant  
PrPSc (c).
Figure 2. Representative Western blot of PrPres from Bv109I inoculated with GSS cases. (a) PrPres from 
Bv109I inoculated with an A117V case in comparison with the starting inoculum; for a lane with PrPres from 
Bv109I a longer exposure of the blot is also included (asterisk). (b) PrPres from Bv109I inoculated with a F198S 
case in comparison with the starting inoculum. (c) PrPres from Bv109I inoculated with P102L cases #5 (left 
panel), #6 (middle panel) and #7 (right panel), along with the starting inocula. Note that Bv109I inoculated with 
case #6 accumulated either small PrPres fragments (lane 2, middle panel) or 21 kDa PrPres (lanes 3 and 4). All 
membranes were probed with 9A2.
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GSS with P102L mutation. To investigate whether distinct PrPres patterns observed in GSS P102L cases 
correlated with biological properties other than pathological phenotypes, we selected brain tissues from three 
unrelated GSS P102L cases, either methionine homozygous or heterozygous at PRNP codon 129: case #5, 
Figure 3. Histological and immunohistochemical analysis of Bv109I infected with F198S and P102L. 
Serial sections of hippocampus from Bv109I inoculated with F198S (a,b) and P102L (d,e,g,h) were analyzed by 
haematoxylin and eosin staining (a,d,g) or by immunohistochemistry for PrPSc (b,e,h). Panels (c,f,i) show higher 
magnifications from sections in panels (b,e,h). Sections in panels (a-f) show the hippocampus from Bv109I that 
accumulated 7–8 kDa PrPres, those in panels (g–i) show the hippocampus from Bv109I that accumulated 21 kDa 
PrPres. Panels (j,k,l,m) show higher magnifications of florid plaques in the stratum lacunoso-moleculare of the 
hippocampus (j) and cerebral cortex (k,l,m) from Bv109I that accumulated 21 kDa PrPres, stained with haematoxylin 
and eosin (j), immunohistochemistry for PrPSc (k), Bielschowsky silver staining (l) and Thioflavin-S (m).
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with both 21 kDa and 8 kDa PrPres; case #6, with 21 kDa and 8 kDa PrPres in cerebral cortex and only 8 kDa 
PrPres in cerebellum; and case #7, with only 8 kDa PrPres in all affected areas (Supplementary Table S1 and 
Supplementary Fig. S3).
Brain homogenate from frontal cortex of case #5 caused terminal disease in 6/8 animals after mean survival 
time of 363 dpi (Table 1). Despite that the original inoculum contained both 21 and 8 kDa PrPres types, only 
∼ 8 kDa PrPres was found in affected voles (Fig. 2c).
Of case #6, we selected brain homogenates from frontal cortex, with 21 and 8 kDa PrPres, and from cerebellum, 
with only 8 kDa PrPres (Supplementary Fig. S3). The cerebellar inoculum resulted in partial attack rate and short 
survival times, with Bv109I showing terminal neurological disease at 153 ± 9 dpi (Table 1) and accumulation of 
~7–8 kDa PrPres only. In contrast, the frontal cortex inoculum from the same case induced two distinct pheno-
types: one Bv109I was affected at 265 dpi and showed only ~7–8 kDa PrPres, while seven voles showed clinical 
signs much later (at ~700 dpi) and accumulated 21 kDa PrPres (Fig. 2c).
Finally, both frontal cortex and cerebellum from case #7 (characterized by the presence of only 8 kDa PrPres) 
transmitted very efficiently, causing disease in 14/16 animals at 208 ± 58 dpi and in 13/13 voles at 171 ± 53 dpi, 
respectively (Table 1). By western blot, all vole brains showed PrPres fragments of ~7–8 kDa (Fig. 2c).
The neuropathological pattern in affected voles accumulating 7–8 kDa PrPres was similar in all cases and was 
characterized by spongiform degeneration with prominent involvement of white matter tracts, hippocampus 
and cerebral cortices, similar to voles inoculated with A117V and F198S GSS (Fig. 3d–f). Voles challenged with 
case #6 P102L that accumulated 21 kDa PrPres displayed a remarkably different neuropathological and immu-
nohistochemical pattern. Medium and large vacuoles were found in several areas of grey matter (Fig. 3g,j), 
mainly involving thalamus, striatum, hippocampus, geniculate nucleus, and cerebral cortex, with much less 
white matter involvement. By immunohistochemistry, punctuate PrPSc deposits were mainly found in cerebral 
cortex, hippocampus (Fig. 3h,i), thalamus and striatum. In some animals, we also observed florid plaques in 
thalamus, hippocampus (Fig. 3j) and cerebral cortex (Fig. 3k–m). Immunohistochemistry for PrPSc (Fig. 3k), 
Bielschowsky silver staining (Fig. 3l) and Thioflavin-S fluorescence (Fig. 3m) confirmed that these were indeed 
PrP-amyloid plaques. Furthermore, PET-blot analysis showed that plaques consisted of protease resistant PrPSc 
(Supplementary Fig. S4).
Biochemical phenotypes of PrPSc in GSS-inoculated voles. We noticed that in some experi-
ment the ~7–8 kDa PrPres observed in voles infected with P102L GSS appeared slightly larger than PrPres from 
A117V-infected voles by direct comparison in western blot (data not shown). We recently reported that PrPres 
types associated with P102L and A117V mutations can be discriminated by the presence of the N-terminal 
epitope of mAb 12B2 (amino acid 83–89, human numbering), which is mostly cleaved by PK in A117V cases, but 
not in P102L (Fig. 4a,b)10, so we directly compared PrPres from human inocula (cases #1 and #5) and recipient 
voles in replica blots probed with mAbs 9A2 and 12B2, directed to flanking epitopes in the N-terminus of PrPres 
(Fig. 4a). We found that PrPres from voles matched their human counterparts, showing faithful propagation of the 
Figure 4. Different internal PrPres fragments in voles inoculated with GSS cases. (a) schematic 
representation of PrPc and PrPres fragments with epitopes of mAbs 12B2 and 9A2 that allow discrimination 
of N-terminal PK cleavage sites of P102L and A117V PrPres fragments. (b) Western blot of PrPres fragments 
from Bv109I (Bv) inoculated with A117V (case #1) and P102L (case #5), along with the respective human 
inocula (Hu). Replica blots were probed with 9A2 and 12B2. (c) Western blot of PrPres fragments from Bv109I 
inoculated with GSS cases. Replica blots were probed with 9A2 and 12B2 to discriminate PrPres types based on 
N-terminal PK cleavage. Bv109I samples analyzed in panel (b) were used as internal controls in panel (c), with 
A117V-infected Bv in the first lane and P102L-infected Bv in the last lane. In this representative set of samples, 
the 12B2 epitope was mainly lost in voles infected with A117V and F198S and in all but two voles infected with 
P102L case #7.
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PrPres N-terminal PK-cleavage after passage in voles (Fig. 4b), suggesting that vole-passaged GSS A117V or P102L 
cases might have conformationally distinct PrPSc distinguishable by the presence or absence of the 12B2 epitope 
in PrPres, resulting in ~7 kDa and ~8 kDa PrPres fragments in vole-passaged GSS cases #1 and #5, respectively.
We used the 12B2 antibody to further characterize the internal PrPres fragments accumulated in most of 
the GSS-infected bank voles. PrPres from all voles inoculated with A117V and F198S showed the same molec-
ular weight (~7 kDa) and the same N-terminal cleavage site (depicted by the partial loss of 12B2 mAb epitope 
in Fig. 4c). In contrast, voles inoculated with P102L cases contained PrPres fragments with the 12B2 epitope, 
with some brains also showing PrPres fragments without the 12B2 epitope, similar to those observed in brains 
of A117V- and F198S-inoculated voles (Fig. 4c). Figure 5 summarizes our biochemical typing of PrPres in 
GSS-infected bank voles. Overall, the PrPres type did not vary among voles infected with A117V or F198S GSS 
cases, while we observed three different molecular types of PrPSc in voles infected with P102L, characterized by 
PrPres of 7 kDa, 8 kDa or 21 kDa PrPres (Fig. 5, upper panel). Different PrPres types were also identified among voles 
inoculated with the identical inocula: case #6 produced either 7 kDa or 21kDa PrPres; case #7 produced either 7 or 
8 kDa PrPres (Fig. 5, upper panel). Amalgamating all of our data, we found a correlation between survival periods 
and PrPSc types (Fig. 5, lower panel): 7 kDa PrPres accumulated in bank voles with the short survivals, 8 kDa PrPres 
was observed in voles with intermediate survivals, and 21 kDa PrPres was observed only in very long survivors. 
This correlation suggests that each of the three PrPres molecular types encipher distinct biological properties.
Discussion
GSS has been at the center of a long debate among pathologists and prionologists based on atypical molecular and 
pathological features, broad variability of disease phenotypes (sometimes even within the same family)20,21,34–36 
and inconsistent transmissibility in experimental models. Indeed, notwithstanding a recent report of low effi-
ciency transmission of GSS A117V in transgenic mice expressing homologous human 117V PrP22, there is no 
definitive evidence that GSS phenotypes with 8 kDa PrPres can transmit disease and propagate infectious prions.
We inoculated seven distinct GSS cases into Bv109I and observed disease transmission in all cases. Overall, 
85/113 voles challenged with brain homogenates from different GSS patients developed a fatal neurological 
illness, most of them between 3 and 7 months post-challenge. Infected voles showed all cardinal neuropatholog-
ical and molecular features of prion diseases, including spongiform degeneration and deposition of PK-resistant 
PrPSc. Furthermore, GSS A117V infected vole brains were able to induce the same disease phenotype in recipient 
voles within 3–4 months after challenge, proving that a prion agent propagated in the brains of infected animals. 
These findings imply that brains of GSS patients harbor infectious prions with transmissibility features similar to 
those found in other human and animal TSEs.
Why GSS replication in recipient hosts has remained elusive is not clear. The ability to propagate heterologous 
PrP species seems to be especially limited for GSS associated with 8 kDa PrPres. Indeed, beside the reported ina-
bility of GSS with 8 kDa PrPres to infect primates, mice and transgenic mouse lines, only mutant proteins were 
found in 8 kDa PrPres fragments from patients with P102L mutation11,37 suggesting inefficient templating of 8 kDa 
PrPres even with wild type human PrP. In this context, bank vole PrP appears to have been pivotal for proving the 
transmissibility of GSS. Accumulating evidence suggests that the remarkable susceptibility of bank voles to TSEs 
Figure 5. Summary of the different PrPres types detected in voles inoculated with GSS cases. The upper 
graph shows the PrPres types (symbols) and survival times (y axis) of Bv109I inoculated with GSS cases as 
indicated (x axis). Red symbols indicate 12B2-negative PrPres of ~7 kDa, black symbols indicate 12B2-positive 
PrPres of ~8 kDa, and green symbols indicate 21 kDa PrPres. The same data and symbols were used for the 
graph in the lower panel, which shows the PrPres type of individual Bv109I ordered by their survival time 
irrespective of the group inocula. The survival time varied significantly depending on their PrPres type (ANOVA, 
P < 0.0001). By two-tailed t-test comparisons, voles with ~7 kDa PrPres showed a survival time shorter than 
those with ~8 kDa PrPres (P < 0.0001) or with 21 kDa PrPres (P < 0.0001), and voles with ~8 kDa PrPres showed a 
survival time shorter than those with ~21 kDa PrPres (P < 0.0001).
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is primarily due to peculiar features of the bank vole PrP amino acid sequence. Transgenic expression of bank 
vole PrP in mice conferred a vole-like susceptibility to several TSEs38, and transgenic mouse lines over-expressing 
bank vole PrP with isoleucine at codon 109 spontaneously develop a transmissible neurological disease39. Some 
studies suggest that the presence of asparagines in or near the β 2-α 2 loop might create a permissive PrP sequence 
able to overcome some species barriers25,30,40. The unexpected lack of transmission barrier for human GSS A117V, 
despite several amino acid mismatches between human and vole PrPs, supports this hypothesis.
P102L, A117V and F198S GSS cases displayed varying transmission efficiencies. Brain extracts from two 
A117V mutation patients induced a highly aggressive TSE in voles, which faithfully reproduced the PrPSc molec-
ular feature of the human counterpart and propagated without transmission barrier, providing definitive evidence 
for transmissibility of this GSS subtype. In the recent study reporting partial transmission of GSS A117V, the 
authors explained the low efficiency of transmission as resulting from instability of A117V-derived abnormal PrP, 
which was found to be labile and detectable in Tg mouse brains only using suitable conditions22. In contrast, we 
found PrPSc accumulated in brains of voles easily detectable in western blots after standard PK digestion, even 
after repeated freeze-thawing (data not shown), similar to that found in brain tissues from A117V patients (this 
study and ref. 10). These differences might be due to the specific GSS cases investigated, or to variation in western 
blot conditions between the two studies. However, it is also noteworthy that Asante and colleagues22 used a mouse 
line over-expressing PrP, providing a stoichiometric context for PrPSc aggregation and propagation different from 
that in human and vole brains, which may have affected the stability and propagation characteristics of PrPSc 
conformers.
We also present here the first evidence that F198S GSS cases produce transmissible prions, although the abil-
ity of our two cases to induce disease in bank voles was clearly different (Table 1). This finding was unexpected, 
especially in light of their overlapping biochemical features10, although the lower amount of PrPres in case #4 com-
pared to case #3 could provide a potential explanation for the observed discrepancy. Another explanation might 
be that case #3 was valine homozygous at codon 129, a molecular feature associated with early onset of disease14, 
while case #4 was methionine/valine heterozygous.
Based on previous evidence that GSS P102L cases with 21 kDa PrPres, but not with 8 kDa PrPres only, were 
associated with “true” infectivity5, we analyzed three P102L cases representing the spectrum of molecular varia-
bility observed in P102L patients. Our results indisputably show that all cases were transmissible in voles. Close 
scrutiny of the transmission efficiencies of the various inocula ruled out any major role of 21 kDa PrPres in deter-
mining transmissibility. In fact, shorter survival times and higher transmission rates were observed in voles inoc-
ulated with tissues containing 8 kDa PrPres only (cerebellum of case #5 and brain tissues from case #6) compared 
with those inoculated with tissues containing both, 21 kDa and 8 kDa PrPres (Table 1), indicating that PrPSc species 
generating 8 kDa PrPres fragments are also associated with prion infectivity in P102L GSS. Interestingly, an inoc-
ulum containing both 21 kDa and 8 kDa PrPres types (frontal cortex from case #6), resulted in the propagation of 
7 kDa PrPres in an individual vole after a short survival period, and of 21 kDa PrPres in the remaining voles after 
much longer survival times, suggesting that PrPSc types associated with 21 kDa or 7–8 kDa PrPres might behave as 
independent transmissible PrPSc species.
Even taking into consideration the variable presence of 21 kDa and 8 kDa PrPres species in the GSS P102L 
patients studied, it is difficult to explain the variable efficiency of transmission that we observed. Tissues 
that induced the highest transmission rates were not those with the highest PrPres content (compare data in 
Supplementary Fig. S3 and Table 1). All of our P102L cases segregated with methionine at codon 129 on the 
mutant allele but carried either valine (#5 and #7) or methionine (#6) at codon 129 of the unmutated PrP allele, 
which may have contributed to transmission variability. Indeed, it has been shown that PrPSc deriving from the 
non mutated allele contributes to molecular variability observed in P102L cases and increase the spectrum of 
PrPSc conformers37,41. Within the limited set of P102L GSS patients studied here at least three different molecu-
lar phenotypes were derived in voles, which partially matched those present in the respective inocula (Fig. 4c). 
Although subpassages are required to establish if different strains evolved in voles, the distinct neuropathological 
pattern observed in voles with 21 kDa PrPres and the correlation between PrPres type and survival time (Fig. 4d) 
support the hypothesis that GSS patients might harbor different prion strains, which could contribute to clinical 
and pathological heterogeneity. As Bv109I appears to be the first animal model able to faithfully propagate GSS, 
further investigation of the relationships between clinicopathological phenotypes, PrPSc conformers, and prion 
strains in families with GSS is warranted.
Methods
Human inocula. Patients were referred to the National Prion Disease Pathology Surveillance Center, 
Cleveland, OH (ID #1–4, 6, 7) and to the Italian National Registry of CJD at the Istituto Superiore di Sanità, Rome, 
Italy (ID #5). Clinicopathologic features, PrP polymorphisms and mutations, and brain areas sampled for analysis 
are reported in Supplementary Table S1. Coronal sections of human brain tissues were obtained at autopsy and 
stored at − 80 °C until use. Informed consent to use human autopsy material for research purposes was obtained 
from all subjects. Clinical data and relevant hospital records were coded and handled according to the protocols 
approved by the Ethical Committee and Institutional Review Board of Case Western Reserve University to protect 
patients’ identities. The use human autopsy material for research has been approved by UHCMC IRB #05-14-
09. Data collection and use of material for GSS case #5 was approved by the Ethical Committee of the Istituto 
Superiore di Sanità.
Animals. Bv109I voles were obtained from the breeding colony at the Istituto Superiore di Sanità. The 
research protocol, approved by the Service for Biotechnology and Animal Welfare of the ISS and authorized by 
the Italian Ministry of Health, adhered to the guidelines contained in the Italian Legislative Decree 116/92, which 
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transposed the European Directive 86/609/EEC on Laboratory Animal Protection, and then in the Legislative 
Decree 26/2014, which transposed the European Directive 2010/63/UE on Laboratory Animal Protection.
Preparation of brain homogenates and bioassays. Tissues were homogenized at 10% (w/v) in phos-
phate buffered saline (PBS) and stored at -80 °C. Groups of eight-week-old Bv109I were inoculated intracerebrally 
with 20 μ l of homogenate into the left cerebral hemisphere, under ketamine anaesthesia (ketamine 0.1 μ g/g). All 
animals were individually identified by a passive integrated transponder. The animals were examined twice a week 
until neurological signs appeared, after which they were examined daily. Diseased animals were culled with car-
bon dioxide at the terminal stage of the disease, but before neurological impairment was such as to compromise 
their welfare, in particular their ability to drink and feed adequately. Survival time was calculated as the interval 
between inoculation and culling or death. ANOVA and unpaired t test statistical analyses for survival times of 
voles were carried out by GraphPad Prism software.
The brain from each animal was removed and cut sagittally into two parts: one stored at − 80 °C and one fixed 
in formalin.
Neuropathology. Histology, immunohistochemistry and PET-blot analysis were performed on 
formalin-fixed tissues as previously described27,29. Briefly, brains were trimmed at standard coronal levels, embed-
ded in paraffin wax, cut at 6 μ m and stained with haematoxylin and eosin, 0.05% Thioflavin-S, or Bielschowsky 
silver. PrP immunolabeling in immunohistochemistry and PET-blot was performed using the 6C2 mAb (epitope 
on bank vole PrP 111–116). Glial fibrillary acidic protein (GFAP) immunolabelling was performed with poly-
clonal rabbit anti-cow GFAP (1:500, Dako-Cytomation).
PrPres analysis and western blotting. Brain homogenates (20% w/v) were prepared as previously 
described31. After adding an equal volume of 100 mM Tris-HCl containing 4% sarkosyl, the homogenates were 
incubated for 30 min at 37 °C with gentle shaking. Proteinase K (Sigma-Aldrich) was added at a final concentra-
tion of 100 μ g/ml and then the samples were incubated for 1 h at 55 °C with gentle shaking. Protease treatment 
was stopped with 3 mM PMSF (Sigma-Aldrich). Aliquots of samples were added with an equal volume of isopro-
panol/butanol (1:1 v/v) and centrifuged at 20,000 g for 5 min. Supernatants were discarded and the pellets were 
resuspended in denaturing sample buffer (NuPAGE LDS Sample Buffer, Invitrogen) and heated for 10 min at 
90 °C. Electrophoresis and western blotting were performed as previously described31. The monoclonal antibodies 
used and their epitope on bank vole PrP were as follow: 9A2 (99–101), 12B2 (89–93), SAF84 (163–169), SAF32 
(octarepeat).
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